Free Trial

West Pharmaceutical Services (WST) Stock Price, News & Analysis

$288.60
-0.39 (-0.13%)
(As of 10/17/2024 ET)

About West Pharmaceutical Services Stock (NYSE:WST)

Key Stats

Today's Range
$286.21
$292.83
50-Day Range
$286.48
$314.79
52-Week Range
$265.00
$413.70
Volume
939,625 shs
Average Volume
551,448 shs
Market Capitalization
$20.94 billion
P/E Ratio
41.05
Dividend Yield
0.28%
Price Target
$442.75
Consensus Rating
Moderate Buy

Company Overview

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

West Pharmaceutical Services Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
100th Percentile Overall Score

WST MarketRank™: 

West Pharmaceutical Services scored higher than 100% of companies evaluated by MarketBeat, and ranked 5th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    West Pharmaceutical Services has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    West Pharmaceutical Services has received no research coverage in the past 90 days.

  • Read more about West Pharmaceutical Services' stock forecast and price target.
  • Earnings Growth

    Earnings for West Pharmaceutical Services are expected to grow by 17.60% in the coming year, from $6.42 to $7.55 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of West Pharmaceutical Services is 41.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.32.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of West Pharmaceutical Services is 41.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.15.

  • Price to Earnings Growth Ratio

    West Pharmaceutical Services has a PEG Ratio of 10.53. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    West Pharmaceutical Services has a P/B Ratio of 7.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about West Pharmaceutical Services' valuation and earnings.
  • Percentage of Shares Shorted

    2.00% of the float of West Pharmaceutical Services has been sold short.
  • Short Interest Ratio / Days to Cover

    West Pharmaceutical Services has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in West Pharmaceutical Services has recently decreased by 7.69%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    West Pharmaceutical Services has a dividend yield of 0.27%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    West Pharmaceutical Services has been increasing its dividend for 31 years.

  • Dividend Coverage

    The dividend payout ratio of West Pharmaceutical Services is 11.38%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, West Pharmaceutical Services will have a dividend payout ratio of 10.60% next year. This indicates that West Pharmaceutical Services will be able to sustain or increase its dividend.

  • Read more about West Pharmaceutical Services' dividend.
  • Percentage of Shares Shorted

    2.00% of the float of West Pharmaceutical Services has been sold short.
  • Short Interest Ratio / Days to Cover

    West Pharmaceutical Services has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in West Pharmaceutical Services has recently decreased by 7.69%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    West Pharmaceutical Services has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for West Pharmaceutical Services this week, compared to 7 articles on an average week.
  • Search Interest

    3 people have searched for WST on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, West Pharmaceutical Services insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $308,700.00 in company stock.

  • Percentage Held by Insiders

    Only 0.53% of the stock of West Pharmaceutical Services is held by insiders.

  • Percentage Held by Institutions

    93.90% of the stock of West Pharmaceutical Services is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about West Pharmaceutical Services' insider trading history.
Receive WST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for West Pharmaceutical Services and its competitors with MarketBeat's FREE daily newsletter.

WST Stock News Headlines

DBS Sticks to Their Buy Rating for West Pharmaceutical Services (WST)
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
West to Host Third-Quarter 2024 Conference Call
See More Headlines

WST Stock Analysis - Frequently Asked Questions

West Pharmaceutical Services' stock was trading at $352.12 on January 1st, 2024. Since then, WST stock has decreased by 18.0% and is now trading at $288.60.
View the best growth stocks for 2024 here
.

West Pharmaceutical Services, Inc. (NYSE:WST) posted its quarterly earnings results on Thursday, July, 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts' consensus estimates of $1.74 by $0.22. The company's revenue for the quarter was down 6.9% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of West Pharmaceutical Services: Drug Delivery Assets From Plastef Investissements SA, Medimop Medical Projects Ltd., The Tech Group Inc., Tech Group Europe Limited (dba West), Tech Group Grand Rapids Inc. (dba West), TGPR Holdings Limited, WD SG Pte. Ltd., and others.

West Pharmaceutical Services' top institutional investors include Rockland Trust Co. (0.08%), Creative Planning (0.07%), Bright Rock Capital Management LLC (0.06%) and McCollum Christoferson Group LLC (0.06%). Insiders that own company stock include Eric Mark Green, Thomas W Hofmann, Quintin J Lai, Annette F Favorite, Bernard Birkett, Cindy Reiss-Clark, Silji Abraham, Charles Witherspoon and Chad Winters.
View institutional ownership trends
.

Shares of WST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that West Pharmaceutical Services investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Home Depot (HD), Chevron (CVX) and Netflix (NFLX).

Company Calendar

Last Earnings
7/25/2024
Ex-Dividend for 8/7 Dividend
7/31/2024
Dividend Payable
8/07/2024
Today
10/17/2024
Next Earnings (Confirmed)
10/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
CUSIP
95530610
Employees
10,600
Year Founded
1923

Price Target and Rating

Average Stock Price Target
$442.75
High Stock Price Target
$536.00
Low Stock Price Target
$375.00
Potential Upside/Downside
+53.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$593.40 million
Pretax Margin
21.25%

Debt

Sales & Book Value

Annual Sales
$2.95 billion
Cash Flow
$9.95 per share
Book Value
$39.31 per share

Miscellaneous

Free Float
72,158,000
Market Cap
$20.94 billion
Optionable
Optionable
Beta
1.01

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NYSE:WST) was last updated on 10/17/2024 by MarketBeat.com Staff
From Our Partners